PURPOSE: One important mechanism for chemoresistance of tumours is overexpression of the adenosine triphosphate-binding cassette transporter P-glycoprotein (Pgp). Pgp reduces intracellular concentrations of chemotherapeutic drugs. The aim of this study was to compare the suitability of the radiolabelled Pgp inhibitors [(11)C]tariquidar and [(11)C]elacridar with the Pgp substrate radiotracer (R)-[(11)C]verapamil for discriminating tumours expressing low and high levels of Pgp using small-animal PET imaging in a murine breast cancer model. METHODS: Murine mammary carcinoma cells (EMT6) were continuously exposed to doxorubicin to generate a Pgp-overexpressing, doxorubicin-resistant cell line (EMT6AR1.0 cells). Both cell lines were subcutaneously injected into female athymic nude mice. One week after implantation, animals underwent PET scans with [(11)C]tariquidar (n = 7), [(11)C]elacridar (n = 6) and (R)-[(11)C]verapamil (n = 7), before and after administration of unlabelled tariquidar (15 mg/kg). Pgp expression in tumour grafts was evaluated by Western blotting. RESULTS: [(11)C]Tariquidar showed significantly higher retention in Pgp-overexpressing EMT6AR1.0 compared with EMT6 tumours: the mean ± SD areas under the time-activity curves in scan 1 from time 0 to 60 min (AUC(0-60)) were 38.8 ± 2.2 min and 25.0 ± 5.3 min (p = 0.016, Wilcoxon matched pairs test). [(11)C]Elacridar and (R)-[(11)C]verapamil were not able to discriminate Pgp expression in tumour models. Following administration of unlabelled tariquidar, both EMT6Ar1.0 and EMT6 tumours showed increases in uptake of [(11)C]tariquidar, [(11)C]elacridar and (R)-[(11)C]verapamil. CONCLUSION: Among the tested radiotracers, [(11)C]tariquidar performed best in discriminating tumours expressing high and low levels of Pgp. Therefore [(11)C]tariquidar merits further investigation as a PET tracer to assess Pgp expression levels in solid tumours.
PURPOSE: One important mechanism for chemoresistance of tumours is overexpression of the adenosine triphosphate-binding cassette transporter P-glycoprotein (Pgp). Pgp reduces intracellular concentrations of chemotherapeutic drugs. The aim of this study was to compare the suitability of the radiolabelled Pgp inhibitors [(11)C]tariquidar and [(11)C]elacridar with the Pgp substrate radiotracer (R)-[(11)C]verapamil for discriminating tumours expressing low and high levels of Pgp using small-animal PET imaging in a murinebreast cancer model. METHODS:Murine mammary carcinoma cells (EMT6) were continuously exposed to doxorubicin to generate a Pgp-overexpressing, doxorubicin-resistant cell line (EMT6AR1.0 cells). Both cell lines were subcutaneously injected into female athymic nude mice. One week after implantation, animals underwent PET scans with [(11)C]tariquidar (n = 7), [(11)C]elacridar (n = 6) and (R)-[(11)C]verapamil (n = 7), before and after administration of unlabelled tariquidar (15 mg/kg). Pgp expression in tumour grafts was evaluated by Western blotting. RESULTS: [(11)C]Tariquidar showed significantly higher retention in Pgp-overexpressing EMT6AR1.0 compared with EMT6 tumours: the mean ± SD areas under the time-activity curves in scan 1 from time 0 to 60 min (AUC(0-60)) were 38.8 ± 2.2 min and 25.0 ± 5.3 min (p = 0.016, Wilcoxon matched pairs test). [(11)C]Elacridar and (R)-[(11)C]verapamil were not able to discriminate Pgp expression in tumour models. Following administration of unlabelled tariquidar, both EMT6Ar1.0 and EMT6 tumours showed increases in uptake of [(11)C]tariquidar, [(11)C]elacridar and (R)-[(11)C]verapamil. CONCLUSION: Among the tested radiotracers, [(11)C]tariquidar performed best in discriminating tumours expressing high and low levels of Pgp. Therefore [(11)C]tariquidar merits further investigation as a PET tracer to assess Pgp expression levels in solid tumours.
Authors: Florian Bauer; Claudia Kuntner; Jens P Bankstahl; Thomas Wanek; Marion Bankstahl; Johann Stanek; Severin Mairinger; Bernd Dörner; Wolfgang Löscher; Markus Müller; Thomas Erker; Oliver Langer Journal: Bioorg Med Chem Date: 2010-06-22 Impact factor: 3.641
Authors: Ronan J Kelly; Deborah Draper; Clara C Chen; Robert W Robey; William D Figg; Richard L Piekarz; Xiaohong Chen; Erin R Gardner; Frank M Balis; Aradhana M Venkatesan; Seth M Steinberg; Tito Fojo; Susan E Bates Journal: Clin Cancer Res Date: 2010-11-16 Impact factor: 12.531
Authors: Claudia Kuntner; Jens P Bankstahl; Marion Bankstahl; Johann Stanek; Thomas Wanek; Gloria Stundner; Rudolf Karch; Rebecca Brauner; Martin Meier; Xiaoqi Ding; Markus Müller; Wolfgang Löscher; Oliver Langer Journal: Eur J Nucl Med Mol Imaging Date: 2009-12-17 Impact factor: 9.236
Authors: P Kannan; C John; S S Zoghbi; C Halldin; M M Gottesman; R B Innis; M D Hall Journal: Clin Pharmacol Ther Date: 2009-07-22 Impact factor: 6.875
Authors: Bernd Dörner; Claudia Kuntner; Jens P Bankstahl; Marion Bankstahl; Johann Stanek; Thomas Wanek; Gloria Stundner; Severin Mairinger; Wolfgang Löscher; Markus Müller; Oliver Langer; Thomas Erker Journal: J Med Chem Date: 2009-10-08 Impact factor: 7.446
Authors: Karen A Kurdziel; Joseph D Kalen; Jerry I Hirsch; John D Wilson; Rakesh Agarwal; Daniel Barrett; Harry D Bear; James F McCumiskey Journal: Nucl Med Biol Date: 2007-07-05 Impact factor: 2.408
Authors: Jame Abraham; Maureen Edgerly; Richard Wilson; Clara Chen; Ann Rutt; Susan Bakke; Rob Robey; Andrew Dwyer; Barry Goldspiel; Frank Balis; Olaf Van Tellingen; Susan E Bates; Tito Fojo Journal: Clin Cancer Res Date: 2009-05-05 Impact factor: 12.531
Authors: Severin Mairinger; Thomas Wanek; Claudia Kuntner; Yaprak Doenmez; Sabine Strommer; Johann Stanek; Elena Capparelli; Peter Chiba; Markus Müller; Nicola A Colabufo; Oliver Langer Journal: Nucl Med Biol Date: 2012-09-13 Impact factor: 2.408
Authors: Martin Bauer; Rudolf Karch; Markus Zeitlinger; Johann Stanek; Cécile Philippe; Wolfgang Wadsak; Markus Mitterhauser; Walter Jäger; Helmuth Haslacher; Markus Müller; Oliver Langer Journal: J Nucl Med Date: 2013-07-05 Impact factor: 10.057
Authors: Florian Bauer; Thomas Wanek; Severin Mairinger; Johann Stanek; Michael Sauberer; Claudia Kuntner; Zahida Parveen; Peter Chiba; Markus Müller; Oliver Langer; Thomas Erker Journal: Eur J Pharmacol Date: 2012-09-26 Impact factor: 4.432
Authors: Pavitra Kannan; András Füredi; Sabina Dizdarevic; Thomas Wanek; Severin Mairinger; Jeffrey Collins; Theresa Falls; R Michael van Dam; Divya Maheshwari; Jason T Lee; Gergely Szakács; Oliver Langer Journal: Eur J Nucl Med Mol Imaging Date: 2019-11-15 Impact factor: 9.236